Adding Opdivo in First-Line Shows Promise in HER2+ Esophagogastric Cancer

(MedPage Today) -- A combination of the PD-1 inhibitor nivolumab (Opdivo) plus trastuzumab and chemotherapy (mFOLFOX6) was effective as first-line therapy for patients with HER2 (ERBB2)-positive esophagogastric adenocarcinoma, according to results...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news